WEBULL
News
MBX
34.69
-7.95%
-3.00
MBX Biosciences Executives to Present at Major Healthcare Investor Conferences
Reuters · 8h ago
Weekly Report: what happened at MBX last week (0202-0206)?
Weekly Report · 2d ago
MBX Biosciences Raises $87 Million in ATM Offering
TipRanks · 5d ago
Weekly Report: what happened at MBX last week (0126-0130)?
Weekly Report · 02/02 09:48
A Look At MBX Biosciences (MBX) Valuation After New Barclays Overweight Coverage
Simply Wall St · 02/01 18:22
How Investors Are Reacting To MBX Biosciences (MBX) Adding Veteran CFO Laurie Stelzer To Its Board
Simply Wall St · 01/31 07:18
Add Up The Parts: IHE Could Be Worth $96
NASDAQ · 01/29 12:07
MBX Biosciences Price Target Announced at $66.00/Share by Barclays
Dow Jones · 01/28 14:54
MBX Biosciences Initiated at Overweight by Barclays
Dow Jones · 01/28 14:54
Barclays Initiates Coverage On MBX Biosciences with Overweight Rating, Announces Price Target of $66
Benzinga · 01/28 14:45
U.S. RESEARCH ROUNDUP- Boeing, Carvana, UnitedHealth
Reuters · 01/28 07:23
MBX Biosciences initiated with an Overweight at Barclays
TipRanks · 01/27 21:31
Weekly Report: what happened at MBX last week (0119-0123)?
Weekly Report · 01/26 09:49
MBX Biosciences Appoints Laurie Stelzer to Board, Audit Chair
TipRanks · 01/22 13:33
MBX Biosciences appoints Laurie Stelzer to board of directors
TipRanks · 01/22 13:17
MBX Biosciences Inc. Files Initial Statement of Beneficial Ownership for Director Laurie Stelzer
Reuters · 01/22 13:07
MBX Biosciences Appoints Laurie Stelzer as Board Director and Audit Committee Chair
Reuters · 01/22 13:00
Press Release: MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair
Dow Jones · 01/22 13:00
*MBX Biosciences Appoints Laurie Stelzer to Bd of Directors as Audit Committee Chair
Dow Jones · 01/22 13:00
Assessing MBX Biosciences (MBX) Valuation After Guggenheim’s Supportive Obesity Drug Updates
Simply Wall St · 01/21 20:13
More
Webull provides a variety of real-time MBX stock news. You can receive the latest news about MBX Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About MBX
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. It has built its proprietary Precision Endocrine Peptide platform to develop precision peptide therapies that are designed to overcome key limitations of current peptide therapies. Its product candidates and programs include MBX 2109, MBX 1416 and Obesity portfolio. MBX 2109 is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. MBX 1416 is designed to be a long-acting glucagon-like peptide-1 (GLP-1), receptor antagonist, as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. MBX 4291 is designed to be a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide, receptor co-agonist prodrug.